These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 30342077)

  • 1. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
    Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
    J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
    Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
    Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
    Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
    J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained secretion of anti-tumor necrosis factor α monoclonal antibody from ex vivo genetically engineered dermal tissue demonstrates therapeutic activity in mouse model of rheumatoid arthritis.
    Zafir-Lavie I; Miari R; Sherbo S; Krispel S; Tal O; Liran A; Shatil T; Badinter F; Goltsman H; Shapir N; Benhar I; Neil GA; Panet A
    J Gene Med; 2017 Aug; 19(8):. PubMed ID: 28658716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
    Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
    Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis.
    Werner MS; Aras S; Morgan AR; Roamer J; Param NJ; Olagbegi K; Lamontagne RJ; Greig JA; Wilson JM
    Cancer Gene Ther; 2024 May; 31(5):766-777. PubMed ID: 38480976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
    Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
    PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases.
    Kanojia D; Balyasnikova IV; Morshed RA; Frank RT; Yu D; Zhang L; Spencer DA; Kim JW; Han Y; Yu D; Ahmed AU; Aboody KS; Lesniak MS
    Stem Cells; 2015 Oct; 33(10):2985-94. PubMed ID: 26260958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models.
    Hu J; Ljubimova JY; Inoue S; Konda B; Patil R; Ding H; Espinoza A; Wawrowsky KA; Patil C; Ljubimov AV; Black KL
    PLoS One; 2010 Apr; 5(4):e10108. PubMed ID: 20419092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
    Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
    Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo.
    Rybakova Y; Kowalski PS; Huang Y; Gonzalez JT; Heartlein MW; DeRosa F; Delcassian D; Anderson DG
    Mol Ther; 2019 Aug; 27(8):1415-1423. PubMed ID: 31160223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and Preliminary Clinical Evaluation of Genetically Transduced Dermal Tissue Implants for the Sustained Secretion of Erythropoietin and Interferon α.
    Shapir N; Miari R; Blum S; Schwartz D; Chernin G; Neil GA; Afik D; Panet A
    Hum Gene Ther Clin Dev; 2015 Dec; 26(4):216-27. PubMed ID: 26684446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
    Wyatt EA; Davis ME
    Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injectable hydrogels for the sustained delivery of a HER2-targeted antibody for preventing local relapse of HER2+ breast cancer after breast-conserving surgery.
    Chen X; Wang M; Yang X; Wang Y; Yu L; Sun J; Ding J
    Theranostics; 2019; 9(21):6080-6098. PubMed ID: 31534538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Wang W; He H; Marín-Ramos NI; Zeng S; Swenson SD; Cho HY; Fu J; Beringer PM; Neman J; Chen L; Schönthal AH; Chen TC
    Neuro Oncol; 2021 Oct; 23(10):1656-1667. PubMed ID: 33659980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral transduction of the HER2-extracellular domain expands trastuzumab-based photoimmunotherapy for HER2-negative breast cancer cells.
    Shimoyama K; Kagawa S; Ishida M; Watanabe S; Noma K; Takehara K; Tazawa H; Hashimoto Y; Tanabe S; Matsuoka J; Kobayashi H; Fujiwara T
    Breast Cancer Res Treat; 2015 Feb; 149(3):597-605. PubMed ID: 25616354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer.
    Nunes T; Pons T; Hou X; Van Do K; Caron B; Rigal M; Di Benedetto M; Palpant B; Leboeuf C; Janin A; Bousquet G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):306. PubMed ID: 31299997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer.
    Wang G; Qiu J; Wang R; Krause A; Boyer JL; Hackett NR; Crystal RG
    Cancer Gene Ther; 2010 Aug; 17(8):559-70. PubMed ID: 20448672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.